Who is sponsoring NCT01315314?

NCT01315314 is sponsored by Kyungpook National University Hospital.

What condition does NCT01315314 study?

NCT01315314 studies Kidney Failure, Chronic, Disorders Associated With Peritoneal Dialysis.

What drugs are being tested in NCT01315314?

Interventions: Balance, Fresenius Medical Care, Germany.

What is the status of NCT01315314?

NCT01315314 is currently COMPLETED.

Last reviewed 2011-03-16 · How we verify

Effects of Neutral pH and Low Glucose Degradation Product-containing Peritoneal Dialysis Fluid on Systemic Markers of Inflammation and Endothelial Dysfunction: a Randomized, Controlled 1-year Follow-up Study

NCT01315314 Phase 4 COMPLETED

The purpose of this study is to evaluate the effects of neutral pH and low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF) on systemic inflammation and endothelial dysfunction markers in incident PD patients.

Details

Lead sponsor	Kyungpook National University Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	146
Start date	2005-10
Completion	2008-04

Conditions

Kidney Failure, Chronic
Disorders Associated With Peritoneal Dialysis

Interventions

Balance, Fresenius Medical Care, Germany

Primary outcomes

Inflammation-endothelial-dysfunction index (IEDI) — Baseline and 12 months
Inflammation-endothelial-dysfunction index (IEDI) is a composite score derived from measurement of serum levels of CRP (high sensitivity assay), soluble VCAM-1 and soluble ICAM-1. Changes between the groups will be tested by analysis of covariance (ANCOVA) with baseline values as covariates. Serial data will also be analyzed using a linear mixed model.

Countries

South Korea